PPT-ASCO 2019 NSCLC - PARP & Chemotherapy

ASCO 2019 NSCLC PARP amp Chemotherapy REF Study Study details Line Drug BiomarkerSubgroup N Primary endpoint Secondary endpoints 1 arapatxBodyatcPr marL50800 marR50800 marT50800 marB50800 horzOverflowoverflowalnL w4445asolidFillasrgbClr val000000asolidFillamiter lim400000alnLalnR w4445asolidFillasrgbClr val000000asolidFillamiter lim400000alnRalnTasolidFillasrgbClr val000000asolidFillamiter lim400000alnTalnB w4445asolidFillasrgbClr val000000asolidFillamiter lim400000alnBanoFillatcPratcatcatxBodyabodyPralstStyleapapPr algnl defTabSz457200adefRPr sz1800apPrararPrasym typefaceHelvetica NeuearPr. Ranee Mehra, MD. Fox Chase Cancer Center. Philadelphia, PA. Disclosures. Consulting – Novartis, Bristol Myers Squib. Spouse is employee of GSK. Acknowledgment: J. Weiss. Ras-Raf-MEK-ERK1/2 MAP . kinase. Le Chevalier, . MD. The Role of Translational Research . in . NSCLC. Outline of Talk. The importance of translational research in improving treatment of NSCLC. Key remaining unmet needs. Overview of promising approaches/agents in the future treatment of NSCLC . Nathan Pennell, M.D., Ph.D.. September 6, 2014. Objectives. Discuss the role of chemotherapy in molecularly defined populations. Discuss the addition of chemo and/or bevacizumab (Avastin) to targeted therapy. MD. The Evolving Treatment Landscape in NSCLC: Congress Updates. Outline of Talk. Provide a brief overview of current advances in the treatment of NSCLC. EGFR-targeted agents . ALK-EML4 targeted agents . Chapter 16; Pages 797 to 815A. also Section 16.11: Drug Resistance. Folder Title: CxChemoPart1. Updated: . April 23, 2018. Therapeutic Modality Options. Surgery. Radiation: X-Ray; Photodynamic Therapy; Thermal Ablation; Microwave; . Presented By Olivia Pagani at 2014 ASCO Annual Meeting. TEXT and SOFT. Presented By Olivia Pagani at 2014 ASCO Annual Meeting. TEXT and SOFT Worldwide Collaborative. Presented By Olivia Pagani at 2014 ASCO Annual Meeting. Lisa McCluskey, MD. Gynecologic Oncologist. June 16, 2015. Compass Oncology . in partnership with . Ovarian . Cancer Alliance of Oregon & SW . Washington. What. is Ovarian Cancer. ?. The most common type of Ovarian Cancer that starts from . proceedings from the live CME event and may include . the use of trade names and other raw, unedited content. . Moderator. Neil Love, MD. Faculty . Oncology Grand Rounds. . Emerging Strategies in Non-Small Cell Lung Cancer. Prediction. . and. . Data Sorting. Zhengtao. Li/06-24-2019. Introduction. https://www.ppdi.com/About/About-Drug-Discovery-and-Development. What . medchem. should focus?. IP. Target engagement. ADME property. Kamil Konopka. Department of Oncology, University Hospital in Cracow. Lung cancer epidemiology. Most common malignancy worldwide. 14% of all new cancers are lung cancers. Lung cancer (NSCLC&SCLC) is the second most common cancer in both men and women (excluding skin cancers). . 5. th. most commonly diagnosed cancer in Australia. 8.9% of new cancer diagnoses. In 2009: . 10,193 cases (. 6034 . men, 4159 women). Projection to . 2020.  . 13,640. Mortality. In 2010 most common cause of cancer death. Chemotherapy Alone for Unresectable . Locally Advanced Pancreatic Cancer . Supported by educational grants from AstraZeneca, Bristol Myers Squibb, and Daiichi Sankyo, Inc.. CCO Independent Conference Highlights*. Addressing Practical Clinical Questions Across the Metastatic Lung Cancer Continuum. Friday, October 11, 2019. 6:15 PM – 7:45 PM . Chicago, Illinois. Faculty. . Moderator. Joel W Neal, MD, PhD. Nasser H Hanna, MD. Osp. . Pertini-S.Eugenio-CTO. Therapeutic. . approach. . to. . HER 2 . breast. . cancer. . in . metastatic. . setting. Lisa Carey, SABCS 2018. La malattia HER2 positiva: . Trastuzumab. Key Phase III HER2 Positive MBC Trials.